Limits...
Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.

Markkula A, Simonsson M, Rosendahl AH, Gaber A, Ingvar C, Rose C, Jernström H - Int. J. Cancer (2014)

Bottom Line: The COX2 rs5277 (306G>C) polymorphism has been associated with inflammation-associated cancers.Minor allele(C) frequency was 16.1%.Chemotherapy-treated G/G-carriers with a breast volume ≥ 850 ml had an increased risk of early events irrespective of ER status, adjusted HR 8.99 (1.14-70.89).

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier estimates of breast cancer-free survival among chemotherapy-treated patients in relation to COX2 rs5277 genotype and breast volume. As this is an ongoing cohort, there are fewer patients with longer follow-up times. (a) In relation to breast volume (Log Rank; p = 0.17). (b) In relation to COX2 rs5277 genotype (Log Rank; p = 0.034). (c) In relation to breast volume and COX2 rs5277 genotype (Log Rank, 3 df; p = 0.050). Adjusted HR 8.99 (95% CI 1.14–70.89; p = 0.037).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4225481&req=5

fig03: Kaplan–Meier estimates of breast cancer-free survival among chemotherapy-treated patients in relation to COX2 rs5277 genotype and breast volume. As this is an ongoing cohort, there are fewer patients with longer follow-up times. (a) In relation to breast volume (Log Rank; p = 0.17). (b) In relation to COX2 rs5277 genotype (Log Rank; p = 0.034). (c) In relation to breast volume and COX2 rs5277 genotype (Log Rank, 3 df; p = 0.050). Adjusted HR 8.99 (95% CI 1.14–70.89; p = 0.037).

Mentions: Chemotherapy-treated patients with a breast volume ≥850 ml did not have an increased risk of early events compared to patients with a breast volume <850 ml ( Fig. 3a; Log Rank 1 df; p = 0.17). Chemotherapy-treated G/G carriers had an increased risk of early events compared to C-allele carriers, irrespective of ER status ( Fig. 3b; Log Rank 1 df; p = 0.034).


Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.

Markkula A, Simonsson M, Rosendahl AH, Gaber A, Ingvar C, Rose C, Jernström H - Int. J. Cancer (2014)

Kaplan–Meier estimates of breast cancer-free survival among chemotherapy-treated patients in relation to COX2 rs5277 genotype and breast volume. As this is an ongoing cohort, there are fewer patients with longer follow-up times. (a) In relation to breast volume (Log Rank; p = 0.17). (b) In relation to COX2 rs5277 genotype (Log Rank; p = 0.034). (c) In relation to breast volume and COX2 rs5277 genotype (Log Rank, 3 df; p = 0.050). Adjusted HR 8.99 (95% CI 1.14–70.89; p = 0.037).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4225481&req=5

fig03: Kaplan–Meier estimates of breast cancer-free survival among chemotherapy-treated patients in relation to COX2 rs5277 genotype and breast volume. As this is an ongoing cohort, there are fewer patients with longer follow-up times. (a) In relation to breast volume (Log Rank; p = 0.17). (b) In relation to COX2 rs5277 genotype (Log Rank; p = 0.034). (c) In relation to breast volume and COX2 rs5277 genotype (Log Rank, 3 df; p = 0.050). Adjusted HR 8.99 (95% CI 1.14–70.89; p = 0.037).
Mentions: Chemotherapy-treated patients with a breast volume ≥850 ml did not have an increased risk of early events compared to patients with a breast volume <850 ml ( Fig. 3a; Log Rank 1 df; p = 0.17). Chemotherapy-treated G/G carriers had an increased risk of early events compared to C-allele carriers, irrespective of ER status ( Fig. 3b; Log Rank 1 df; p = 0.034).

Bottom Line: The COX2 rs5277 (306G>C) polymorphism has been associated with inflammation-associated cancers.Minor allele(C) frequency was 16.1%.Chemotherapy-treated G/G-carriers with a breast volume ≥ 850 ml had an increased risk of early events irrespective of ER status, adjusted HR 8.99 (1.14-70.89).

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Show MeSH
Related in: MedlinePlus